Head and Neck Cancers: Epidemiology Forecast to 2026

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3995
Buy Report View Sample

Published: March 30, 2018 Report Code: GDHCER180-18-ST

Select Item

Head and neck cancers usually begin in the squamous cells that line the moist mucosal surfaces of the tissues and organs of the head and neck—more than 83% of all oral cavity and pharynx cancers are squamous cell carcinomas. They are the ninth most common malignancy in the world, with high mortality rates in the developing countries

10-year epidemiological forecasts of the diagnosed incident cases of HNCs are provided. HNCs are grouped into the following, in this report:
1. Cancers of the lip, oral cavity, pharynx, and larynx cancer (ICD-10 = C00–C06, C09–C10, C12–C14, and C32)
2. Oropharynx cancer (ICD-10 = C10)
3. Nasopharynx cancer (ICD-10 = C11)
4. Other head and neck cancer sites – salivary gland and nose, sinuses, and other related structures cancer (ICD-10 = C07–C08 and C30–C31)

To forecast the diagnosed incident cases and the five-year diagnosed prevalent cases of HNCs in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies or cancer registries that provided the diagnosed incidence or observed or relative survival rates for these cancers in the 7MM. GlobalData estimate that the diagnosed incident cases of HNCs in the 7MM will increase from 154,300 cases in 2016 to 177,034 cases in 2026, at an Annual Growth Rate (AGR) of 1.47% over the forecast period. Throughout the forecast period, the US will have the highest number of diagnosed incident cases of HNCs, followed by Japan.

Scope

The Head and Neck Cancers Epidemiology Report and Model provide an overview of the risk factors and global trends of head and neck cancers in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

10-year epidemiological forecasts of the diagnosed incident cases of HNCs are provided and segmented into the following groups: cancers of the lip, oral cavity, pharynx, and larynx cancer; oropharynx cancer; nasopharynx cancer; and other sites. Histology distribution and, clinical stage at diagnosis, risk factors, and diagnosed five-year prevalent cases are available for some of the groups.

The head and neck cancers epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The head and neck cancers Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global head and neck cancers market.

Quantify patient populations in the global head and neck cancers market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for head and neck cancers therapeutics in each of the markets covered.

Understand magnitude of patient groups in each of the cancer subgroups and their relevant patient characteristics.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Head and Neck Cancers: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods – Population

3.4.3 Forecast Assumptions and Methods – Diagnosed Incident Cases of HNCs

3.4.4 Forecast Assumptions and Methods – Five-Year Diagnosed Prevalent Cases of HNCs

3.4.5 Forecast Assumptions and Methods – Diagnosed Incident Cases of HNCs by Histology Distribution

3.4.6 Forecast Assumptions and Methods – Diagnosed Incident Cases of HNC by Clinical Stages at Diagnosis for Squamous Cell Carcinoma

3.4.7 Forecast Assumptions and Methods – Diagnosed Incident Cases of Oropharynx Cancer by Risk Factor (HPV+ and HPV-)

3.4.8 Forecast Assumptions and Methods – Diagnosed Incident Cases of Nasopharynx Cancer by Risk Factor (EBV+)

3.5 Epidemiological Forecast for HNCs (2016–2026)

3.5.1 Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer

3.5.2 Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer

3.5.3 Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer

3.5.4 Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Histology Distribution

3.5.5 Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma

3.5.6 Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer

3.5.7 Diagnosed Incident Cases of Oropharynx Cancer by Histology Distribution and by Risk Factor (HPV)

3.5.8 Diagnosed Incident Cases of Nasopharynx Cancer by Histology Distribution and by Risk Factor (EBV)

3.5.9 Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer

3.5.10 Age-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer

3.5.11 Sex-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer

3.5.12 Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Histology Distribution

3.5.13 Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma

3.5.14 Five-Year Diagnosed Prevalent Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of the Analysis

3.6.3 Strengths of the Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

Table

Table 1: Risk Factors and Comorbid Conditions Associated with HNCs

Table 2: 7MM, Diagnosed Incident Cases of Oropharynx Cancer by Histology Distribution and by Risk Factor (HPV), Both Sexes, Ages ≥18 Years, N, 2016

Table 3: 7MM, Diagnosed Incident Cases of Nasopharynx Cancer by Histology Distribution and by Risk Factor (EBV+), Both Sexes, Ages ≥18 Years, N, 2016

Figures

Figure 1: 7MM, Diagnosed Incident Cases of HNCs, Both Sexes, Ages ≥18 Years, N, 2016 and 2026

Figure 2: 7MM, Age-Standardized Diagnosed Incidence of Lip, Oral Cavity, Pharynx, and Larynx Cancer (Cases per 100,000 Population), Men, Ages ≥18 Years, 2016–2026

Figure 3: 7MM, Age-Standardized Diagnosed Incidence of Lip, Oral Cavity, Pharynx, and Larynx Cancer (Cases per 100,000 Population), Women, Ages ≥18 Years, 2016–2026

Figure 4: 7MM, Age-Standardized Diagnosed Incidence of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer (Cases per 100,000 Population), Men, Ages ≥18 Years, 2016–2026

Figure 5: 7MM, Age-Standardized Diagnosed Incidence of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer (Cases per 100,000 Population), Women, Ages ≥18 Years, 2016–2026

Figure 6: 7MM, Sources Used, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer; Oropharynx Cancer; Nasopharynx Cancer; Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer

Figure 7: 7MM, Sources Used, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer; Oropharynx Cancer; Nasopharynx Cancer by Histology Distribution

Figure 8: 7MM, Sources Used, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Histology Distribution

Figure 9: 7MM, Sources Used, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma

Figure 10: 7MM, Sources Used, Diagnosed Incident Cases of Oropharynx Cancer; Nasopharynx Cancer; Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma

Figure 11: 7MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer

Figure 12: 7MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Nasopharynx Cancer; Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer

Figure 13: 7MM, Sources Used, Diagnosed Incident Cases of Oropharynx Cancer by Risk Factor (HPV+ and HPV-)

Figure 14: 7MM, Sources Used, Diagnosed Incident Cases of Nasopharynx Cancer by Risk Factor (EBV+)

Figure 15: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, Both Sexes, Ages ≥18 Years, N, 2016

Figure 16: 7MM, Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, Both Sexes, N, 2016

Figure 17: 7MM, Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, Ages ≥18 Years, N, 2016

Figure 18: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Histology Distribution, Both Sexes, Ages ≥18 Years, N, 2016

Figure 19: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma, Both Sexes, Ages ≥18 Years, N, 2016

Figure 20: 7MM, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, Both Sexes, Ages ≥18 Years, N, 2016

Figure 21: 7MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer, Both Sexes, Ages ≥18 Years, N, 2016

Figure 22: 7MM, Age-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer, Both Sexes, Ages ≥18 Years, N, 2016

Figure 23: 7MM, Sex-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer, Ages ≥18 Years, N, 2016

Figure 24: 7MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Histology Distribution, Both Sexes, Ages ≥18 Years, N, 2016

Figure 25: 7MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma, Both Sexes, Ages ≥18 Years, N, 2016

Figure 26: 7MM, Five-Year Diagnosed Prevalent Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer, Both Sexes, Ages ≥18 Years, N, 2016

Frequently asked questions

Head and Neck Cancers: Epidemiology Forecast to 2026 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

Most Popular
$7,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Head and Neck Cancers: Epidemiology Forecast to 2026 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Head and Neck Cancers: Epidemiology Forecast to 2026 in real time.

  • Access a live Head and Neck Cancers: Epidemiology Forecast to 2026 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more